Center for Acute Respiratory Failure and Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians & Surgeons, New York, New York.
Department of Anesthesia, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
JAMA. 2019 Mar 5;321(9):846-857. doi: 10.1001/jama.2019.0555.
Adjusting positive end-expiratory pressure (PEEP) to offset pleural pressure might attenuate lung injury and improve patient outcomes in acute respiratory distress syndrome (ARDS).
To determine whether PEEP titration guided by esophageal pressure (PES), an estimate of pleural pressure, was more effective than empirical high PEEP-fraction of inspired oxygen (Fio2) in moderate to severe ARDS.
DESIGN, SETTING, AND PARTICIPANTS: Phase 2 randomized clinical trial conducted at 14 hospitals in North America. Two hundred mechanically ventilated patients aged 16 years and older with moderate to severe ARDS (Pao2:Fio2 ≤200 mm Hg) were enrolled between October 31, 2012, and September 14, 2017; long-term follow-up was completed July 30, 2018.
Participants were randomized to PES-guided PEEP (n = 102) or empirical high PEEP-Fio2 (n = 98). All participants received low tidal volumes.
The primary outcome was a ranked composite score incorporating death and days free from mechanical ventilation among survivors through day 28. Prespecified secondary outcomes included 28-day mortality, days free from mechanical ventilation among survivors, and need for rescue therapy.
Two hundred patients were enrolled (mean [SD] age, 56 [16] years; 46% female) and completed 28-day follow-up. The primary composite end point was not significantly different between treatment groups (probability of more favorable outcome with PES-guided PEEP: 49.6% [95% CI, 41.7% to 57.5%]; P = .92). At 28 days, 33 of 102 patients (32.4%) assigned to PES-guided PEEP and 30 of 98 patients (30.6%) assigned to empirical PEEP-Fio2 died (risk difference, 1.7% [95% CI, -11.1% to 14.6%]; P = .88). Days free from mechanical ventilation among survivors was not significantly different (median [interquartile range]: 22 [15-24] vs 21 [16.5-24] days; median difference, 0 [95% CI, -1 to 2] days; P = .85). Patients assigned to PES-guided PEEP were significantly less likely to receive rescue therapy (4/102 [3.9%] vs 12/98 [12.2%]; risk difference, -8.3% [95% CI, -15.8% to -0.8%]; P = .04). None of the 7 other prespecified secondary clinical end points were significantly different. Adverse events included gross barotrauma, which occurred in 6 patients with PES-guided PEEP and 5 patients with empirical PEEP-Fio2.
Among patients with moderate to severe ARDS, PES-guided PEEP, compared with empirical high PEEP-Fio2, resulted in no significant difference in death and days free from mechanical ventilation. These findings do not support PES-guided PEEP titration in ARDS.
ClinicalTrials.gov Identifier NCT01681225.
通过调整呼气末正压(PEEP)来抵消胸膜压力,可能会减轻急性呼吸窘迫综合征(ARDS)中的肺损伤并改善患者的预后。
确定通过食管压力(PES)指导的 PEEP 滴定(胸膜压力的估计值)是否比经验性高 PEEP-吸入氧分数(Fio2)更有效,用于中度至重度 ARDS。
设计、地点和参与者:在北美 14 家医院进行的 2 期随机临床试验。2012 年 10 月 31 日至 2017 年 9 月 14 日期间,共纳入 200 名机械通气的中度至重度 ARDS 患者(Pao2:Fio2 ≤200 mm Hg),年龄 16 岁及以上;2018 年 7 月 30 日完成了长期随访。
参与者被随机分配到 PES 指导的 PEEP(n=102)或经验性高 PEEP-Fio2(n=98)组。所有参与者均接受低潮气量通气。
主要结果是 28 天内包含死亡和幸存者无机械通气天数的综合评分排名。预设的次要结局包括 28 天死亡率、幸存者无机械通气天数和需要抢救治疗。
共纳入 200 名患者(平均[标准差]年龄,56[16]岁;46%为女性)并完成了 28 天的随访。主要复合终点在治疗组之间没有显著差异(PES 指导的 PEEP 组更有利结局的概率:49.6%[95%CI,41.7%至 57.5%];P=0.92)。在 28 天,102 名患者中(32.4%)分配到 PES 指导的 PEEP 组和 98 名患者中(30.6%)分配到经验性 PEEP-Fio2 组的 33 名患者死亡(风险差异,1.7%[95%CI,-11.1%至 14.6%];P=0.88)。幸存者无机械通气天数无显著差异(中位数[四分位间距]:22[15-24]vs 21[16.5-24]天;中位数差值,0[95%CI,-1 至 2]天;P=0.85)。分配到 PES 指导的 PEEP 组的患者接受抢救治疗的可能性显著降低(4/102[3.9%]vs 12/98[12.2%];风险差异,-8.3%[95%CI,-15.8%至-0.8%];P=0.04)。其他 7 个预设的次要临床结局均无显著差异。不良事件包括气胸,在 PES 指导的 PEEP 组中发生了 6 例,在经验性 PEEP-Fio2 组中发生了 5 例。
在中度至重度 ARDS 患者中,与经验性高 PEEP-Fio2 相比,PES 指导的 PEEP 滴定并未在死亡和无机械通气天数方面产生显著差异。这些发现不支持在 ARDS 中进行 PES 指导的 PEEP 滴定。
ClinicalTrials.gov 标识符 NCT01681225。